Tandem Diabetes Care (TNDM)
NASDAQ:TNDM
Want to see TNDM full AI Analyst Report?
TNDM Stock Chart & Stats
$20.61
-$0.45(-1.21%)
At close: 4:00 PM EST
$20.61
-$0.45(-1.21%)
Day’s Range― - ―
52-Week Range$9.98 - $29.65
Previous CloseN/A
Volume336.73K
Average Volume (3M)2.46M
Market Cap
$996.41M
Enterprise Value$1.58B
Total Cash (Recent Filing)$570.26M
Total Debt (Recent Filing)$734.74M
Price to Earnings (P/E)―
Beta0.80
Next Earnings
Aug 05, 2026EPS Estimate
-0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.40
Shares Outstanding68,529,090
10 Day Avg. Volume2,992,252
30 Day Avg. Volume2,459,174
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)9.53
Price to Sales (P/S)1.46
P/FCF Ratio-49.85
Enterprise Value/Market Cap1.59
Enterprise Value/Revenue1.54
Enterprise Value/Gross Profit2.80
Enterprise Value/Ebitda-20.92
Forecast
1Y Price Target
$31.21Price Target Upside51.45% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
EPS Forecast (FY)-0.67
Revenue Forecast (FY)$1.07B
Bulls Say, Bears Say
Bulls Say
International And Pricing OpportunitiesExpanding direct international sales and capturing pharmacy pricing benefits could materially increase revenue and support meaningful gross margin expansion.
New Product AdoptionA tubeless Mobi wearable with an improved control algorithm could raise device adoption, increase pump shipments, and help the company regain market share.
Pharmacy Distribution ExpansionShift to a pharmacy pay-as-you-go model is expected to grow higher-margin recurring supply revenue and improve pricing, creating a compounding annuity effect that can boost long-term revenue and margins.
Bears Say
Competitive Pressure On Patient AdoptionSustained competitive pressure and weaker-than-expected new patient pump growth could limit market share gains and constrain revenue growth.
Execution Risk And ProfitabilityBelow-peer profitability and execution risk could justify a valuation discount, making upside dependent on successful operational execution of strategic changes.
Sustainability Of PerformanceQuarterly outperformance that reflected reduced research and development spending raises concerns about the sustainability of current margins and future product innovation.
Tandem Diabetes Care News
TNDM FAQ
What was Tandem Diabetes Care’s price range in the past 12 months?
Tandem Diabetes Care lowest stock price was $9.98 and its highest was $29.65 in the past 12 months.
What is Tandem Diabetes Care’s market cap?
Tandem Diabetes Care’s market cap is $996.41M.
When is Tandem Diabetes Care’s upcoming earnings report date?
Tandem Diabetes Care’s upcoming earnings report date is Aug 05, 2026 which is in 69 days.
How were Tandem Diabetes Care’s earnings last quarter?
Tandem Diabetes Care released its earnings results on May 07, 2026. The company reported -$0.298 earnings per share for the quarter, beating the consensus estimate of -$0.444 by $0.146.
Is Tandem Diabetes Care overvalued?
According to Wall Street analysts Tandem Diabetes Care’s price is currently Undervalued.
Does Tandem Diabetes Care pay dividends?
Tandem Diabetes Care does not currently pay dividends.
What is Tandem Diabetes Care’s EPS estimate?
Tandem Diabetes Care’s EPS estimate is -0.33.
How many shares outstanding does Tandem Diabetes Care have?
Tandem Diabetes Care has 68,529,090 shares outstanding.
What happened to Tandem Diabetes Care’s price movement after its last earnings report?
Tandem Diabetes Care reported an EPS of -$0.298 in its last earnings report, beating expectations of -$0.444. Following the earnings report the stock price went down -16.188%.
Which hedge fund is a major shareholder of Tandem Diabetes Care?
Currently, no hedge funds are holding shares in TNDM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tandem Diabetes Care Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$31.21 (51.45% Upside)
$31.21 (51.45% Upside)
Blogger Sentiment
Bullish
TNDM Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 704.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.4%
Last 30 Days ▼ 8.0%
Last 30 Days ▼ 8.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-31.00%
12-Months-Change
Fundamentals
Return on Equity
-68.29%
Trailing 12-Months
Asset Growth
25.08%
Trailing 12-Months
Company Description
Tandem Diabetes Care
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. It has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
TNDM Company Deck
TNDM Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong operational and financial momentum—record shipments and sales, meaningful margin expansion, positive cash generation, a strengthened balance sheet, international go‑direct progress, and multiple product and integration milestones (Android Mobi, pregnancy clearance, FreeStyle Libre 3+ and G7 compatibility, Mobi Tubeless filing). Management acknowledged manageable near‑term headwinds from infusion set supplier shortages and the early operational friction of the PayGo pharmacy transition, plus some international timing and one‑time effects. Overall, the positive results, clear roadmap for product launches, and reaffirmed FY guidance outweigh the disclosed challenges.View all TNDM earnings summariesTNDM Revenue Breakdown
74.21% U.S.
25.79% International
TNDM Stock 12 Month Forecast
Average Price Target
$31.21
▲(51.45% Upside)
Technical Analysis
Ownership Overview
0.99% Insiders
20.83% Mutual Funds
42.26% Other Institutional Investors
11.12% Public Companies and
Individual Investors